Synlogic announces first industry collaboration with AbbVie to develop a new class of medicines designed to power the microbiome
Multi-year R&D collaboration with AbbVie focused on novel medicines for treatment of inflammatory bowel disease.
Synlogic has signed a multi-year global R&D collaboration with AbbVie. The collaboration is focused on developing novel medicines for the treatment of inflammatory bowel disease (IBD) using Synlogic’s proprietary approach for a new class of synthetic biotic medicines that power the microbiome.
Under the terms of the collaboration, Synlogic will discover, characterize and optimize synthetic biotics-based drug candidates through an R&D program covering a limited number of effectors modulating the IBD pathophysiology, with special emphasis on Crohn’s disease and ulcerative colitis. One of the goals of the multi-year collaboration is to combine AbbVie’s expertise in metabolic and inflammatory diseases with Synlogic’s platform to generate and advance to the clinic a novel, oral probiotic therapeutic candidate. Using Synlogic’s synthetic biotics platform, the novel probiotic drug candidate will be designed with synthetic programmable genetic circuits that can blend with the patient’s microbiome and perform a programmed therapeutic operation involved in the IBD disease process.
“Synlogic’s innovative approach to targeting the microbiome offers a new way to address inflammatory bowel disease,” said Jim Sullivan, vice president, pharmaceutical discovery, AbbVie. “AbbVie is committed to collaborating with scientific leaders with new technologies and therapeutic advances that complement AbbVie’s internal expertise and share our commitment to advancing the standard of care for patients.”
Under the R&D collaboration, AbbVie and Synlogic will evaluate synthetic biotic candidates that modulate certain effectors involved in the IBD pathway and advance them through preclinical development, with AbbVie being responsible for regulatory filings, clinical development and worldwide marketing of any resulting products. Financial terms were not disclosed.
“We are delighted to be working with AbbVie, an innovative leader in treating inflammation and autoimmune diseases. We envision the potential for strong synergy from the combination of AbbVie’s metabolic and inflammation expertise with our novel therapeutic approach of precision programing in the microbiome, opening new ways to create synthetic biotics to address the significant unmet needs for people with IBD,” said Jose-Carlos (JC) Gutiérrez-Ramos, CEO of Synlogic. “This partnership with AbbVie is a part of our overall strategy for enabling the broad potential of our synthetic biotics platform by forging partnerships with pharmaceutical and biotechnology leaders to pursue major disease indications affecting millions of patients, while simultaneously accelerating Synlogic’s internal pipeline in rare orphan diseases toward the clinic.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance